Oncologists and patient advocacy groups pressed for clarity Friday over the price and availability of a newly approved pancreatic cancer drug, one day after the US Food and Drug Administration cleared the treatment based on improved survival data.

The FDA announced approval on August 27, describing it as an advance for pancreatic ductal adenocarcinoma, one of the deadliest common cancers with a five-year survival rate below 13%. Trial results showed measurable extension in overall survival compared with standard chemotherapy.

The Pancreatic Cancer Action Network and clinicians at major US cancer centres said the approval could shift treatment standards. They warned that reimbursement decisions and manufacturing capacity would determine real-world impact, urging the manufacturer to publish pricing and expanded-access details.

Medical societies, including the American Society of Clinical Oncology, were expected to update treatment guidance in response. Insurers and the Centers for Medicare & Medicaid Services face pressure to establish coverage pathways for a patient population with limited options.

Analysts tracking oncology investments said the launch would test whether high-cost targeted therapies can achieve rapid uptake in a disease historically resistant to breakthroughs, with attention turning to the drug's list price and companion diagnostic requirements.